Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.47 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968070 | 0.83 | SLC9A1 (0.64) | SLC9A1SLC9A2NPSR1KMT2ASMN1; SMN2 | |
| SCHEMBL29070079 | 0.81 | SLC9A1 (0.48) | SLC9A1SLC9A2NPSR1KMT2ASMN1; SMN2 | |
| SCHEMBL27371650 | 0.73 | SLC9A1 (0.47) | SLC9A1SLC9A2NPSR1KMT2ASMN1; SMN2 | |
| SCHEMBL5405584 | 0.73 | CDC25B (0.53) | NPSR1KMT2ASMN1; SMN2KDM4ECDC25B | |
| SCHEMBL2593426 | 0.73 | PTK2B (0.58) | NPSR1KMT2ASMN1; SMN2CDC25BPTK2B | |
| SCHEMBL9018714 | 0.72 | PKM (0.50) | NPSR1KMT2ASMN1; SMN2KDM4ECDC25B | |
| SCHEMBL8816549 | 0.71 | SMN1; SMN2 (0.50) | SLC9A1SLC9A2KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL6295085 | 0.71 | KMT2A (0.49) | NPSR1KMT2ASMN1; SMN2KDM4EACE2 | |
| SCHEMBL31401059 | 0.71 | SMN1; SMN2 (0.59) | KMT2ASMN1; SMN2CDC25BPKMMAPT | |
| SCHEMBL6293695 | 0.71 | SMN1; SMN2 (0.59) | KMT2ASMN1; SMN2CDC25BPKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812226-B2 | FOR THERAPY OF RHEUMATOID ARTHRITIS, EFFECTING IMMUNOSUPPRESSION | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | disclosed |
| US-20030040513-A1 | P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | US | disclosed |
| EP-1242396-A1 | NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044213-A1 | NEW P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040513-A1 | P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | P2RX1, P2RX2, P2RX3 | SLC9A1 709/4885SLC9A2 968/4885NPSR1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.